Br J Anaesth:重症监护病房80岁以上患者的短期死亡率研究

2022-05-16 医路坦克 MedSci原创

80岁以上的患者占ICU入院人数的五分之一。这项分析的主要目的是调查欧洲国家之间ICU和30天死亡率的差异,并利用两项大型观察性研究的数据描述医疗支出水平与80岁以上患者死亡率之间的关系。

80岁以上的患者占ICU入院人数的五分之一。尽管老年危重患者的数量在不断增加,但直到最近,关于高龄重症患者(VIP)的流行病学数据一直很少。迄今为止发表的描述危重疾病结局的大型国际研究主要集中在较年轻的患者群体上。以前报告的结果表明,欧洲国家之间住院死亡率的差异与国民收入和医疗费用的差异有关。然而,我们目前对危重患者医疗支出和死亡率之间关系的理解仅限于住院指数。

这项分析的主要目的是调查欧洲国家之间ICU和30天死亡率的差异,并利用两项大型观察性研究的数据描述医疗支出水平与80岁以上患者死亡率之间的关系。

两项国际前瞻性队列研究的多水平分析。我们纳入了来自16个欧洲国家的322个ICU的80岁的患者。主要结果是入院后30天内死亡。结果以n(%)表示,具有95%的可信区间和优势比(OR)。

结果:8457例患者中,2944例(36.9%,35.9%)在30天内死亡。各参与国之间的粗死亡率差异很大(ICU中的粗死亡率从10.1%[6.4e15.6%]到45.1%[41.1e49.2%],30天内从21.3%[16.3e28.9%]到55.3%[51.1e59.5%])。在调整混杂变量后,国家间30天死亡率的差异显著小于ICU间的差异(中位数OR 1.14比1.58)。人均医疗保健支出(OR£0.84/1000美元[0.75e0.94])和社会保险框架(OR£1.43[1.01e2.01])与ICU死亡率相关,但在30天的随访中,这些关系的方向和程度尚不确定。入院量与较低的死亡率有关,在ICU(每1000名ICU每年入院人数中OR£0.81[0.71e0.94])和30天随访中(OR£0.86[0.76e0.97])。

结论:欧洲各地在ICU住院的老年人短期死亡率的明显差异在很大程度上可以归因于入院患者的临床特征的差异。在这一人群中确定的体积与结果的关系需要进一步调查。

文献来源:Fronczek J,  Flaatten H,  Guidet B,Short-term mortality of patients ≥80 years old admitted to European intensive care units: an international observational study.Br J Anaesth 2022 Apr 29

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051776, encodeId=59b72051e76a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 04 10:48:32 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633637, encodeId=b6b3163363eb4, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Mar 19 16:48:32 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368866, encodeId=bc4113688668e, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551226, encodeId=12491551226c7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051776, encodeId=59b72051e76a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 04 10:48:32 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633637, encodeId=b6b3163363eb4, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Mar 19 16:48:32 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368866, encodeId=bc4113688668e, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551226, encodeId=12491551226c7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=)]
    2023-03-19 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051776, encodeId=59b72051e76a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 04 10:48:32 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633637, encodeId=b6b3163363eb4, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Mar 19 16:48:32 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368866, encodeId=bc4113688668e, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551226, encodeId=12491551226c7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051776, encodeId=59b72051e76a6, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 04 10:48:32 CST 2023, time=2023-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633637, encodeId=b6b3163363eb4, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sun Mar 19 16:48:32 CST 2023, time=2023-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368866, encodeId=bc4113688668e, content=<a href='/topic/show?id=3d849596588' target=_blank style='color:#2F92EE;'>#重症监护病房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95965, encryptionId=3d849596588, topicName=重症监护病房)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551226, encodeId=12491551226c7, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Sat May 14 14:48:32 CST 2022, time=2022-05-14, status=1, ipAttribution=)]
    2022-05-14 bioon6

相关资讯

Crit Care:重症监护病房生命体征昼夜节律的意义

ICU患者入住期间生命体征的昼夜节律仍然存在,但对这些节律的定量评估可能会为ICU患者提供预后信息。

JAHA:重症监护患者右心室肺动脉耦联与死亡率的关系

较低的TASV/RVSP比值与心脏重症监护病房患者的短期和长期死亡率增加相关,这些结果提示了RV肺动脉耦连受损作为不良预后的决定因素的重要性。

Crit Care:瘦体重是重症监护病房入院的危险因素

在这项基于人群的队列研究中,瘦体重与入住ICU无关;然而,更大的四肢瘦体重与死亡率降低相关。这表明入住ICU前肌肉状态可能无法预测危重疾病的发展,但与危重疾病发生后更好的生存相关。

Crit Care:欧洲重症监护病房ARDS的流行病学、治疗和预后方面的变化趋势

2002年至2012年间,ARDS的发生频率和结局相对稳定。在机械通气的第一天,高平台压>29 cmH2O和驱动压力>14 cmH2O,而非潮气量>8 ml/kg,与更高的死亡风险相关。

Crit Care:重症监护病房谵妄运动亚型的分布情况

机能减退性谵妄是重症患者中最常见的运动亚型。混合性谵妄在谵妄持续时间、住院时间和死亡率方面的结果最差,并且与其他运动性谵妄亚型相比,接受了更多的药物干预。

Diabetes Care:COVID-19住院的1型糖尿病患者入住重症监护病房、机械通气和死亡率分析

因COVID-19住院的T1DM患者发生严重结局的风险高于非糖尿病患者。T1DM患者ICU/MV的风险高于T2DM患者的主要原因是伴有DKA。这些结果可进一步指导糖尿病治疗和COVID-19预防。